<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput xmlns:ns2="local" id="15730"><DrugName>aminopterin (oral), Syntrix Biosystems</DrugName><DrugSynonyms><Name><Value>Aminopterin</Value></Name><Name><Value>aminopterin, University of Texas/ILEX</Value></Name><Name><Value>aminopterin, University of Medicine &amp; Dentistry of New Jersey</Value></Name><Name><Value>NSC-739</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>aminopterin (oral), Syntrix Biosystems</Value></Name><Name><Value>aminotrexate, Syntrix Biosystems</Value></Name><Name><Value>LD-aminopterin</Value></Name><Name><Value>54-62-6</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="21864">University of Texas System</CompanyOriginator><CompaniesSecondary><Company id="1023036">Syntrix Biosystems Inc</Company><Company id="20638">University of Medicine and Dentistry of New Jersey</Company><Company id="21864">University of Texas System</Company><Company id="23744">ILEX Oncology Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1023036" type="Company"><TargetEntity id="4297453568" type="organizationId">Syntrix Biosystems Inc</TargetEntity></SourceEntity><SourceEntity id="20638" type="Company"><TargetEntity id="4296715677" type="organizationId">University of Medicine and Dentistry of New Jersey</TargetEntity></SourceEntity><SourceEntity id="21864" type="Company"><TargetEntity id="4296333708" type="organizationId">University of Texas System</TargetEntity></SourceEntity><SourceEntity id="23744" type="Company"><TargetEntity id="4295906762" type="organizationId">Ilex Oncology Inc</TargetEntity></SourceEntity><SourceEntity id="1102" type="ciIndication"><TargetEntity id="L20" type="ICD10"></TargetEntity><TargetEntity id="691" type="ICD9"></TargetEntity><TargetEntity id="10012438" type="MEDDRA"></TargetEntity><TargetEntity id="D003876" type="MeSH"></TargetEntity><TargetEntity id="-1439185598" type="omicsDisease"></TargetEntity><TargetEntity id="456" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1705" type="ciIndication"><TargetEntity id="10014733" type="MEDDRA"></TargetEntity><TargetEntity id="D016889" type="MeSH"></TargetEntity><TargetEntity id="-49801714" type="omicsDisease"></TargetEntity><TargetEntity id="597" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1728" type="ciIndication"><TargetEntity id="C91.0" type="ICD10"></TargetEntity><TargetEntity id="204" type="ICD9"></TargetEntity><TargetEntity id="513" type="ORPHANET"></TargetEntity><TargetEntity id="685" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="281" type="ciIndication"><TargetEntity id="L40" type="ICD10"></TargetEntity><TargetEntity id="10037153" type="MEDDRA"></TargetEntity><TargetEntity id="D011565" type="MeSH"></TargetEntity><TargetEntity id="-1735788310" type="omicsDisease"></TargetEntity><TargetEntity id="490" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="291" type="ciIndication"><TargetEntity id="10039073" type="MEDDRA"></TargetEntity><TargetEntity id="D001172" type="MeSH"></TargetEntity><TargetEntity id="-1391695545" type="omicsDisease"></TargetEntity><TargetEntity id="749" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C3">Phase 3 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="1102">Atopic dermatitis</Indication><Indication id="1705">Endometrioid carcinoma</Indication><Indication id="1728">Acute lymphoblastic leukemia</Indication><Indication id="281">Psoriasis</Indication><Indication id="291">Rheumatoid arthritis</Indication><Indication id="651">Cancer</Indication></IndicationsSecondary><ActionsSecondary><Action id="15184">Systemic antipsoriatic product</Action><Action id="1545">Anticancer</Action><Action id="2953">Anti-inflammatory</Action><Action id="59620">Unspecified drug target</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>D5B</Code><Name>SYSTEMIC ANTIPSORIASIS PRODUCTS</Name></Ephmra></EphmraCodes><LastModificationDate>2018-10-16T06:53:25.000Z</LastModificationDate><ChangeDateLast>2018-10-17T00:00:00.000Z</ChangeDateLast><AddedDate>1997-08-15T14:09:51.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="20638" linkType="Company"&gt;&lt;/ulink&gt;&lt;ulink linkID="1023036" linkType="Company"&gt;Syntrix Biosystems&lt;/ulink&gt;, under license from  &lt;ulink linkID="20638" linkType="Company"&gt;University of Medicine and Dentistry of New Jersey&lt;/ulink&gt; (UMDNJ) was developing a formulation of aminopterin (L/D-aminopterin) for the potential oral treatment of psoriasis and rheumatoid arthritis (RA) [&lt;ulink linkID="1211064" linkType="Reference"&gt;1211064&lt;/ulink&gt;], [&lt;ulink linkID="867323" linkType="Reference"&gt;867323&lt;/ulink&gt;], [&lt;ulink linkID="1135306" linkType="Reference"&gt;1135306&lt;/ulink&gt;], [&lt;ulink linkID="1388073" linkType="Reference"&gt;1388073&lt;/ulink&gt;]. In September 2011, phase II  trials for  psoriasis were ongoing [&lt;ulink linkID="1220640" linkType="Reference"&gt;1220640&lt;/ulink&gt;]. In September 2013, the drug was listed as being in phase II development and at that time, phase II trials in RA were expected to be completed  by early 2014 [&lt;ulink linkID="1480427" linkType="Reference"&gt;1480427&lt;/ulink&gt;]. In September 2006, series of two sequential phase II/III trials and NDA filing for psoriasis  were planned [&lt;ulink linkID="1210722" linkType="Reference"&gt;1210722&lt;/ulink&gt;]; in February 2010, this was still the case [&lt;ulink linkID="1172752" linkType="Reference"&gt;1172752&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Syntrix was developing the drug for the potential treatment of acute lymphocytic leukemia (ALL)  and atopic dermatitis[&lt;ulink linkID="1211064" linkType="Reference"&gt; 1211064&lt;/ulink&gt;], [&lt;ulink linkID="867323" linkType="Reference"&gt;867323&lt;/ulink&gt;], [&lt;ulink linkID="1135306" linkType="Reference"&gt;1135306&lt;/ulink&gt;], [&lt;ulink linkID="1388073" linkType="Reference"&gt;1388073&lt;/ulink&gt;]. In September 2011, phase II  trials for  pediatric leukemia and  atopic dermatitis were ongoing [&lt;ulink linkID="1220640" linkType="Reference"&gt;1220640&lt;/ulink&gt;]; however, in September 2013, the drug was no longer listed as under development for these indications [&lt;ulink linkID="1480427" linkType="Reference"&gt;1480427&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;UMDNJ (previously the University of Texas Southwestern) was previously collaborated in the  development of the formulation for ALL. By December 2001, phase III trials, in patients with high risk ALL, had been initiated by the University [&lt;ulink linkID="433421" linkType="reference"&gt;433421&lt;/ulink&gt;]; however, no further development was reported  for  UMDNJ since April 2002.&lt;/para&gt;&lt;para&gt;ILEX Oncology was originally collaborating with the researchers on the development of the formulation for both ALL and endometrial cancer. In March 1997, ILEX was planning to initiate phase II trials that year [&lt;ulink linkID="259438" linkType="reference"&gt;259438&lt;/ulink&gt;]; however, the company discontinued development in the first half of 2000 because of insufficient efficacy in an endometrial cancer study [&lt;ulink linkID="377964" linkType="reference"&gt;377964&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In September 2006, the company planned to file an NDA for psoriasis after the completion of two phase II/III trials [&lt;ulink linkID="1210722" linkType="Reference"&gt;1210722&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Acute Lymphocytic leukemia&lt;/subtitle&gt;In December 2006, at the  48th ASH meeting in Orlando, FL data were presented from a phase IIb pediatric trial in 33 high-risk ALL patients, which tested whether aminopterin could be used at its maximum tolerated dose (4 mg/m2/week in two doses, 12 h apart) in place of methotrexate (MTX) in multi-agent therapy. It was shown to be comparable in efficacy, tolerability, pharmacokinetics and pharmacogenetics to MTX at 25-fold higher doses. Hepatotoxicity was less common  in patients receiving aminopterin compared to those treated with MTX	[&lt;ulink linkID="748868" linkType="Reference"&gt;748868&lt;/ulink&gt;]. In November 2009, similar data were presented showing that, at 45 months, the median three-year event-free survival was 83% in patients aged 10 to 20 years [&lt;ulink linkID="1135653" linkType="Reference"&gt;1135653&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2002, phase II data were also presented at the 38th ASCO meeting in Orlando, FL. Patients with endometrial carcinoma were entered into the trial, and 24 were evaluable. Aminopterin was administered weekly until disease progressed. A partial response was seen in one patient, stable disease in four patients, and increasing tumor in 19 [&lt;ulink linkID="453842" linkType="reference"&gt;453842&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2002, phase II data on aminopterin, were presented at the 93rd AACR meeting in San Francisco, CA. A total of 30 patients were enrolled in a phase II study of aminopterin, including 12 children with ALL, 6 adults with ALL in relapse, and 12 patients with acute myeloblastic leukemia (AML). Among the 12 children with refractory ALL, there were two complete responses and one partial response. Among the six adults with ALL, two had stable disease for two months [&lt;ulink linkID="446784" linkType="reference"&gt;446784&lt;/ulink&gt;]. Similar data were presented previously in December 2001 at the 43rd ASH meeting in Orlando, FL. In addition, six disease stabilizations were achieved at this dose level (2 mg/m2). At this time, a phase III trial was in progress at the same dose in patients with high-risk ALL [&lt;ulink linkID="433421" linkType="reference"&gt;433421&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2000, UMDNJ was continuing with ongoing phase II trials in ALL [&lt;ulink linkID="396518" linkType="reference"&gt;396518&lt;/ulink&gt;], [&lt;ulink linkID="396524" linkType="reference"&gt;396524&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;ILEX discontinued its development of aminopterin in the first half of 2000 following poor results in a phase II trial of persistent, recurrent endometrial cancer [&lt;ulink linkID="377964" linkType="reference"&gt;377964&lt;/ulink&gt;]. The phase II trial was initiated by ILEX in February 1998. The trial was designed to evaluate the antitumor activity of aminopterin in patients with persistent or recurrent endometrial cancer who had failed prior therapy. The trial was also intended to determine the nature and degree of toxicity, and to confirm bioavailability data in this patient population [&lt;ulink linkID="279213" linkType="reference"&gt;279213&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By 1997, an IND had been submitted to the relevant authority, and the drug was in ongoing phase I/II trials; initial results showed positive antitumor activity. Initial phase I results on 23 patients with refractory malignancies showed the maximum tolerated dose was 2 mg/m2, as two doses 12 h apart, weekly, with delayed leucovorin rescue [&lt;ulink linkID="272241" linkType="reference"&gt;272241&lt;/ulink&gt;]. In November 2009, similar data were presented  showing the oral bioavailability of the drug to be 83.5%. Mucositis was the dose limiting toxicity and one complete response was seen in endometrial adenocarcinoma for more than 11 months   [&lt;ulink linkID="1135653" linkType="Reference"&gt;1135653&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 1997, ILEX Oncology began clinical trials for aminopterin in children with ALL who were unresponsive to methotrexate. By this time, the compound had been purified and a new formulation developed. At this time, ILEX intended to apply for Orphan Drug status [&lt;ulink linkID="259438" linkType="reference"&gt;259438&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rheumatoid Arthritis&lt;/subtitle&gt;In November 2009, data showed that a phase II  randomized discontinuation trial for rheumatoid arthritis  was to open late 2010. The study was to demonstrate activity of the drug  in MTX  failures    [&lt;ulink linkID="1135653" linkType="Reference"&gt;1135653&lt;/ulink&gt;]. In July 2012, a dose-ranging, phase II trial was initiated to evaluate the safety, efficacy, and pharmacokinetics of LD-aminopterin. In the study, the patients were randomized to receive placebo, 1 or 3 mg of LD-aminopterin in 1:1:1 ratio [&lt;ulink linkID="1481970" linkType="Reference"&gt;1481970&lt;/ulink&gt;]. In February 2013, a phase II, double-blind, placebo-controlled, randomized dose finding study (&lt;ulink linkID="97845" linkType="Protocol"&gt;NCT01724931&lt;/ulink&gt;; Syntrix-AMT-RA-202) of aminopterin in methotrexate-naive rheumatoid arthritis patients (expected n = 150) was initiated. At that time, the trial was expected to complete in November 2013 [&lt;ulink linkID="1388073" linkType="Reference"&gt;1388073&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Psoriasis&lt;/subtitle&gt;By November 2009, a phase I trial (&lt;ulink linkID="58701" linkType="Protocol"&gt;NCT00937027&lt;/ulink&gt;; Syntrix-AMT-PSO-101) for psoriasis was initiated  [&lt;ulink linkID="1135653" linkType="Reference"&gt;1135653&lt;/ulink&gt;]; in April 2010, the open-label, randomized, crossover trial  in patients (n = 20)  with psoriasis was completed [&lt;ulink linkID="1227276" linkType="Reference"&gt;1227276&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2006, the company planned to initiate a series of two sequential phase II/III trials. The first trial would be a  dose-finding,  12-week, phase II trial  in patients (n = 36) with  moderate-to-severe plaque psoriasis to assess the safety of oral aminopterin. The second trial would be a double-blind, randomized, 26-week, phase III trial   in patients (n = 390) with  moderate-to-severe plaque psoriasis to compare the safety, efficacy and tolerability of oral aminopterin with oral MTX [&lt;ulink linkID="1210722" linkType="Reference"&gt;1210722&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In November 2009, preclinical data were presented. Aminopterin was 43-fold more potent than methotrexate in murine model. The compound was active in a canine model of atopic dermatitis    [&lt;ulink linkID="1135653" linkType="Reference"&gt;1135653&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By August 2008, a preclinical study had demonstrated the safety and tolerability of aminopterin in dogs with atopic dermatitis [&lt;ulink linkID="1211064" linkType="Reference"&gt;1211064&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;By January 2008, Syntrix had received a grant from the NIH for a clinical trial of aminopterin for psoriasis [&lt;ulink linkID="867336" linkType="Reference"&gt;867336&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By January 2008, Syntrix Biosystems was collaborating on the development of the drug [&lt;ulink linkID="867323" linkType="Reference"&gt;867323&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By March 1997, pediatric cancer specialists at the &lt;ulink linkID="25760" linkType="Company"&gt;University of Texas Southwestern Medical Center&lt;/ulink&gt;, led by Dr Barton Kamen, had signed an agreement with ILEX Oncology for development of aminopterin [&lt;ulink linkID="259438" linkType="reference"&gt;259438&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="23744">ILEX Oncology Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2000-08-04T00:00:00.000Z</StatusDate><Source id="377964" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23744">ILEX Oncology Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="1705">Endometrioid carcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2000-08-04T00:00:00.000Z</StatusDate><Source id="377964" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23744">ILEX Oncology Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="1728">Acute lymphoblastic leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2000-08-04T00:00:00.000Z</StatusDate><Source id="377964" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1023036">Syntrix Biosystems Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1728">Acute lymphoblastic leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-09-24T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="21864">University of Texas System</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1728">Acute lymphoblastic leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2000-12-01T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20638">University of Medicine and Dentistry of New Jersey</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1728">Acute lymphoblastic leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2011-09-07T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1023036">Syntrix Biosystems Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1102">Atopic dermatitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-09-24T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1023036">Syntrix Biosystems Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-10-15T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1023036">Syntrix Biosystems Inc</Company><Country id="UA">Ukraine</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-10-15T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="20638">University of Medicine and Dentistry of New Jersey</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1728">Acute lymphoblastic leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2001-12-20T00:00:00.000Z</StatusDate><Source id="433421" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1023036">Syntrix Biosystems Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-11-30T00:00:00.000Z</StatusDate><Source id="1135653" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1023036">Syntrix Biosystems Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1728">Acute lymphoblastic leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-01-14T00:00:00.000Z</StatusDate><Source id="867323" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1023036">Syntrix Biosystems Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1102">Atopic dermatitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-08-28T00:00:00.000Z</StatusDate><Source id="1211064" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="21864">University of Texas System</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1728">Acute lymphoblastic leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1997-08-15T00:00:00.000Z</StatusDate><Source id="248363" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1023036">Syntrix Biosystems Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="281">Psoriasis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-01-14T00:00:00.000Z</StatusDate><Source id="867323" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1023036">Syntrix Biosystems Inc</Company><Country id="UA">Ukraine</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2013-02-28T00:00:00.000Z</StatusDate><Source id="1388073" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20638">University of Medicine and Dentistry of New Jersey</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1728">Acute lymphoblastic leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2000-12-01T00:00:00.000Z</StatusDate><Source id="396518" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23744">ILEX Oncology Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1997-08-15T00:00:00.000Z</StatusDate><Source id="248363" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23744">ILEX Oncology Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1705">Endometrioid carcinoma</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1998-02-25T00:00:00.000Z</StatusDate><Source id="279213" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23744">ILEX Oncology Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1728">Acute lymphoblastic leukemia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1997-08-15T00:00:00.000Z</StatusDate><Source id="248363" type="CORPORATE"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1023036">Syntrix Biosystems Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="20516">US Government</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="21239">Rutgers University</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>c1cc(ccc1C(=O)N[C@@H](CCC(=O)O)C(=O)O)NCc2cnc3c(n2)c(nc(n3)N)N</Smiles></StructureSmiles><Deals><Deal id="111255" title="Syntrix Biosystems and University of Medicine and Dentistry to codevelop aminopterin worldwide"></Deal><Deal id="136678" title="Syntrix to receive funding from the US Government to develop aminotrexate for psoriasis and atopic dermatitis                 "></Deal></Deals><PatentFamilies><PatentFamily id="1091903" number="WO-09408564" title="Composition of antineoplastic agents incorporated in micelles."></PatentFamily><PatentFamily id="1321557" number="US-07235660" title="Facile process for the preparation of high-purity aminopterin"></PatentFamily><PatentFamily id="1542474" number="WO-2010085717" title="Pharmaceutical composition comprising racemic aminopterin"></PatentFamily><PatentFamily id="1618078" number="WO-2006098979" title="Aminopterin dosage forms and methods for inflammatory disorders"></PatentFamily><PatentFamily id="1715281" number="EP-00137640" title="Chain extended analogues of methotrexate and aminopterin"></PatentFamily><PatentFamily id="2299358" number="WO-2013026268" title="Tumor chemotherapeutic drug formulation and preparation method thereof"></PatentFamily><PatentFamily id="2307057" number="EP-00142220" title="Cysteic acid and homocysteic acid analogues of methotrexate and aminopterin"></PatentFamily><PatentFamily id="2310003" number="WO-09004593" title="Desamino-aminopterin and -methotrexate"></PatentFamily><PatentFamily id="2613341" number="WO-2013154774" title="Block copolymers for stable micelles"></PatentFamily><PatentFamily id="3118367" number="CN-105232887" title="A capsule for treating heart failure coronary heart disease and preparation method thereof"></PatentFamily><PatentFamily id="3544323" number="CN-106431984" title="Synthesis method of sodium aminopterin medicine intermediate cyanoacetamide"></PatentFamily><PatentFamily id="3553923" number="CN-105503547" title="Synthesis method of ammonia methotrexate sodium medicine intermediate diethane propylene acraldehyde"></PatentFamily><PatentFamily id="721991" number="WO-2005089767" title="Use of aminopterin for treating cancer and inflammatory disorders"></PatentFamily><PatentFamily id="873793" number="WO-00105405" title="Folylpolyglutamyl synthetase gene transfer to enhance antifolate drug sensitivity"></PatentFamily><PatentFamily id="973653" number="US-04701413" title="Method of producing inosine and/or guanosine"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>2</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Syntrix Biosystems Inc" id="1023036"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Aminopterin LLC" id="1112648"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput>